ClinicalTrials.gg

Program

BIIB147

A development code.

Its studies are mostly in Amyotrophic Lateral Sclerosis, led by Biogen.

Furthest: phase 2, since Sep 28, 20261 company-led study, 1 open or runningNext primary completion: Jan 23, 2034 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen11 open or runningphase 2since Sep 28, 2026Sep 28, 2026Jan 23, 2034phase 2 · NCT07855211

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 28, 2026First study: phase 2 study in Amyotrophic Lateral SclerosisFirst studyNCT07855211 · 69 planned · United States

Ahead

  1. Jan 23, 2034Primary completion: phase 2 study in Amyotrophic Lateral SclerosisNCT07855211

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07855211Amyotrophic Lateral Sclerosis · United States2RecruitingJan 23, 203469

How it is read

Names in the registry

  • “BIIB147”, 1 entry

Codes read as this program: BIIB147.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.